How do I buy Oncology Pharma stock?
Is oncology pharma publicly traded?
Is Oncology Pharma A Good Investment?
holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What is oncology pharmacy trading at?
...
Performance Outlook.
| Previous Close | 3.6350 |
|---|---|
| Day's Range | 3.5500 - 3.6400 |
| 52 Week Range | 2.8500 - 42.7800 |
| Volume | 26,819 |
| Avg. Volume | 143,753 |
Who owns oncology pharma?
The company was founded by Marcel van Heesewijk on March 26, 1993 and is headquartered in San Francisco, CA.
Did ONPH do a reverse split?
Does oncology pharma pay dividends?
What stock is TaaS?
What is TaaS stock worth?
| Previous Close | 0.0130 |
|---|---|
| Open | 0.0130 |
| Day's Range | 0.0122 - 0.8373 |
| 52 Week Range | 0.0122 - 2.0895 |
| Start Date | 2017-03-30 |
What did oncology pharmacy close at today?
| Previous Close | 3.4360 |
|---|---|
| Day's Range | 3.3500 - 3.6000 |
| 52 Week Range | 2.8500 - 42.7800 |
| Volume | 23,067 |
| Avg. Volume | 137,339 |
Is ONPH on the Nasdaq?
Are investors shorting Oncology Pharma?
Oncology Pharma saw a increase in short interest in February. As of February 15th, there was short interest totaling 563,400 shares, an increase of...
Who are Oncology Pharma's key executives?
Oncology Pharma's management team includes the following people: Mr. Chuck Wagner , Pres, Treasurer & Chairman Mr. George Malesek , Interim Chie...
Who are some of Oncology Pharma's key competitors?
Some companies that are related to Oncology Pharma include Upland Software (UPLD) , ChannelAdvisor (ECOM) , Pathfinder Acquisition (PFDR) , Red...
What is Oncology Pharma's stock symbol?
Oncology Pharma trades on the OTCMKTS under the ticker symbol "ONPH."
How do I buy shares of Oncology Pharma?
Shares of ONPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Oncology Pharma's stock price today?
One share of ONPH stock can currently be purchased for approximately $4.01.
How much money does Oncology Pharma make?
Oncology Pharma has a market capitalization of $135.52 million.
How many employees does Oncology Pharma have?
Oncology Pharma employs 1 workers across the globe.
What is Oncology Pharma's official website?
The official website for Oncology Pharma is www.oncology-pharma.com .
What is the ticker symbol for Oncology Pharma?
Oncology Pharma trades on the OTCMKTS under the ticker symbol "ONPH."
Does Oncology Pharma pay dividends?
Oncology Pharma does not currently pay a dividend.
How much did Oncology stock fall in 2021?
The Oncology Pharma Inc. stock price fell by -6.26% on the last day (Monday, 22nd Nov 2021) from $7.67 to $7.19. and has now fallen 3 days in a row. During the day the stock fluctuated 5.70% from a day low at $7.19 to a day high of $7.60. The price has fallen in 7 of the last 10 days and is down by -22.19% for this period. Volume has increased on the last day by 37 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 216 thousand shares were bought and sold for approximately $1.55 million.
Is Oncology Pharma Inc. a negative stock?
Oncology Pharma Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.
Is Oncology Pharma stock a sell signal?
There are few to no technical positive signals at the moment. The Oncology Pharma Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $7.96 and $9.88. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, October 19, 2021, and so far it has fallen -56.42%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.
Is Bollinger Band stock high risk?
This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.41 between high and low, or 5.70%. For the last week, the stock has had a daily average volatility of 6.30% .
Is Oncology Pharma oversold?
Oncology Pharma Inc. is oversold on RSI14 (15). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.
Oncology Pharma Expands on Feasibility Studies and Data
SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc.
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma's New Year Update
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma Meeting Towards Future Developments
SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc.
Oncology Pharma Year End Review and Outlook
SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
Oncology Pharma Research and Vision
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc.
ONPH Target Price
ONPH price target in 14 days: 7.587 USD* upside and 4.783 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Oncology Pharma Inc ( ONPH ) Stock Market info
Recommendations: Buy or sell Oncology Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Oncology Pharma share forecasts, stock quote and buy / sell signals below.
What are the different grades for stocks?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
What is ZER research?
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Does Zackstrade endorse or recommend investment strategies?
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
How to invest in oncology stocks?
Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the cancer industry, track how your stock performs to decide when it’s time to sell.
What is Amgen stock?
discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. Amgen stock opened the day at $243.09 after a previous close of $244.28.
What is Five Prime Therapeutics?
Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies . The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.
What is the company that makes Revlimid?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
What is Cardiff Oncology?
Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer . Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin.
What is Novartis AG?
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.
Can you turn a profit on oncology stocks?
While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest.
How to determine Oncology Pharma value?
Investors typically determine Oncology Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is oncology pharmacy?
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California. Oncology Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. more on Oncology Pharma.
What is the risk premium for Oncology Pharma?
Oncology Pharma market risk premium is the additional return an investor will receive from holding Oncology Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncology Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Oncology Pharma's alpha and beta are two of the key measurements used to evaluate Oncology Pharma's performance over the market, the standard measures of volatility play an important role as well.
How does Oncology Pharma's value differ from its book value?
The market value of Oncology Pharma is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Pharma's value that differs from its market value or its book value, called intrinsic value, which is Oncology Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Pharma's market value can be influenced by many factors that don't directly affect Oncology Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
How many days will it take for Oncology Pharma to move above current price?
Based on a normal probability distribution, the odds of Oncology Pharma to move above the current price in 90 days from now is roughly 97.0 (This Oncology Pharma probability density function shows the probability of Oncology OTC Stock to fall within a particular range of prices over 90 days) .
Can you enter a position in oncology without increasing your portfolio risk?
Our tools can tell you how much better you can do entering a position in Oncology Pharma without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.
Is Oncology Pharma a reactive market?
This indicates Oncology Pharma market returns are reactive to returns on the market. As the market goes up or down, Oncology Pharma is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified.
